Vertex Pharmaceuticals Inc (VRTX.OQ)
79.52USD
4:00pm EDT
$-0.91 (-1.13%)
$80.43
$80.60
$81.63
$78.83
657,159
748,181
$87.46
$38.44
VRTX.OQ
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | $17,807.27 |
| Shares Outstanding (Mil.): | 221.40 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VRTX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 34.45 | 32.18 |
| EPS (TTM): | -2.36 | -- | -- |
| ROI: | -25.32 | -2.81 | 18.91 |
| ROE: | -60.40 | -3.51 | 19.87 |
Vertex posts loss, raises cystic fibrosis sales view
- Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.
UPDATE 3-Vertex posts loss, raises cystic fibrosis sales view
April 30 - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.
Vertex posts quarterly loss as hepatitis C drug sales fall
April 30 - Vertex Pharmaceuticals Inc on Tuesday reported a fourth successive quarterly loss as sales of its hepatitis C drug, Incivek, continued to plunge, but the biotechnology company raised its forecast for sales of a cystic fibrosis drug that has become the focus for investors.
Vertex shares up after successful cystic fibrosis trial
- Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares 54 percent higher in after-hours trading.
UPDATE 2-Vertex shares up after successful cystic fibrosis trial
April 18 - Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares 54 percent higher in after-hours trading.
Vertex cystic fibrosis drug succeeds in combo trial
April 18 - Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares up sharply in after-hours trading.
BRIEF-Vertex soars 49 percent in extended trading
NEW YORK, April 18 - Vertex Pharmaceuticals Inc : * Soars 49 percent in extended trading
UPDATE 2-Vertex hep C drug sales plunge; looks to cystic fibrosis
* Shares fall 2 percent after-hours (Adds analyst, company comment, updates share price)
BRIEF-Vertex Pharmaceuticals shares down 2.1 pct after the bell following results
NEW YORK, Jan 29 - Vertex Pharmaceuticals Inc : * Shares were down 2.1 percent after the bell following the release of its results.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $86.57 | -0.06 |
| Pfizer Inc. (PFE.N) | $27.70 | -0.08 |
| Novartis AG (NOVN.VX) | CHF67.45 | +0.15 |
| Merck & Co., Inc. (MRK.N) | $46.55 | +0.23 |
| Roche Holding Ltd. (ROG.VX) | CHF235.70 | +1.10 |
| Sanofi SA (SASY.PA) | €78.82 | -1.05 |
| GlaxoSmithKline plc (GSK.L) | 1,670.00p | +11.50 |
| AbbVie Inc (ABBV.N) | $42.21 | +0.60 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | -0.48 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
